CL2014003326A1 - Formulación antioxidante inyectable de uso intravenoso de ascorbato de sodio - en altas dosis, y n-acetilcisteína como agentes oxidantes, y deferoxamina como agentes quelante de hierro, más excipientes farmacéuticos; método para su administración y uso en prevenir el daño por repertfusión en pacientes con inferto agudo del miocardío, sometidos a angioplastia caronaria primaria; y kit que la contiene. - Google Patents

Formulación antioxidante inyectable de uso intravenoso de ascorbato de sodio - en altas dosis, y n-acetilcisteína como agentes oxidantes, y deferoxamina como agentes quelante de hierro, más excipientes farmacéuticos; método para su administración y uso en prevenir el daño por repertfusión en pacientes con inferto agudo del miocardío, sometidos a angioplastia caronaria primaria; y kit que la contiene.

Info

Publication number
CL2014003326A1
CL2014003326A1 CL2014003326A CL2014003326A CL2014003326A1 CL 2014003326 A1 CL2014003326 A1 CL 2014003326A1 CL 2014003326 A CL2014003326 A CL 2014003326A CL 2014003326 A CL2014003326 A CL 2014003326A CL 2014003326 A1 CL2014003326 A1 CL 2014003326A1
Authority
CL
Chile
Prior art keywords
repertfusion
deferoxamine
acetylcysteine
injectable
kit
Prior art date
Application number
CL2014003326A
Other languages
English (en)
Inventor
Salinas Ramón Rodrigo
Vergara Gina Sánchez
Dominguez Juan Carlos Prieto
Nayle Rubén Aguayo
Urzua Fernando Florenzano
Araya Juan Guillermo Gormaz
Original Assignee
Univ Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chile filed Critical Univ Chile
Priority to CL2014003326A priority Critical patent/CL2014003326A1/es
Publication of CL2014003326A1 publication Critical patent/CL2014003326A1/es
Priority to PCT/CL2015/050048 priority patent/WO2016086327A1/es
Priority to US15/532,556 priority patent/US20170333393A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14Details; Accessories therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/18Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient
    • B65D81/20Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient under vacuum or superatmospheric pressure, or in a special atmosphere, e.g. of inert gas
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/24Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
    • B65D81/30Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants by excluding light or other outside radiation
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Food Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2014003326A 2014-12-05 2014-12-05 Formulación antioxidante inyectable de uso intravenoso de ascorbato de sodio - en altas dosis, y n-acetilcisteína como agentes oxidantes, y deferoxamina como agentes quelante de hierro, más excipientes farmacéuticos; método para su administración y uso en prevenir el daño por repertfusión en pacientes con inferto agudo del miocardío, sometidos a angioplastia caronaria primaria; y kit que la contiene. CL2014003326A1 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CL2014003326A CL2014003326A1 (es) 2014-12-05 2014-12-05 Formulación antioxidante inyectable de uso intravenoso de ascorbato de sodio - en altas dosis, y n-acetilcisteína como agentes oxidantes, y deferoxamina como agentes quelante de hierro, más excipientes farmacéuticos; método para su administración y uso en prevenir el daño por repertfusión en pacientes con inferto agudo del miocardío, sometidos a angioplastia caronaria primaria; y kit que la contiene.
PCT/CL2015/050048 WO2016086327A1 (es) 2014-12-05 2015-12-04 Formulación antioxidante inyectable de uso intravenoso de ascorbato de sodio - en altas dosis, n-acetilcisteína, y deferoxamina; método de administración y uso en prevenir daño por reperfusión; y kit
US15/532,556 US20170333393A1 (en) 2014-12-05 2015-12-04 Injectable antioxidant formulation for intravenous use of sodium ascorbate in high dosage, n-acetyl cysteine, and deferoxamine; method of administration and use for preventing injury due to reperfusion; and kit

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2014003326A CL2014003326A1 (es) 2014-12-05 2014-12-05 Formulación antioxidante inyectable de uso intravenoso de ascorbato de sodio - en altas dosis, y n-acetilcisteína como agentes oxidantes, y deferoxamina como agentes quelante de hierro, más excipientes farmacéuticos; método para su administración y uso en prevenir el daño por repertfusión en pacientes con inferto agudo del miocardío, sometidos a angioplastia caronaria primaria; y kit que la contiene.

Publications (1)

Publication Number Publication Date
CL2014003326A1 true CL2014003326A1 (es) 2015-03-20

Family

ID=53404099

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003326A CL2014003326A1 (es) 2014-12-05 2014-12-05 Formulación antioxidante inyectable de uso intravenoso de ascorbato de sodio - en altas dosis, y n-acetilcisteína como agentes oxidantes, y deferoxamina como agentes quelante de hierro, más excipientes farmacéuticos; método para su administración y uso en prevenir el daño por repertfusión en pacientes con inferto agudo del miocardío, sometidos a angioplastia caronaria primaria; y kit que la contiene.

Country Status (3)

Country Link
US (1) US20170333393A1 (es)
CL (1) CL2014003326A1 (es)
WO (1) WO2016086327A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20180026A1 (es) 2015-01-27 2018-01-09 Florengale Llc Composicion topica curativa
GR20180100514A (el) * 2018-11-07 2020-06-15 Πανεπιστημιο Πατρων Φαρμακευτικοι συνδυασμοι και κιτ για την προληψη ή την θεραπεια του πονου και αλλων επιπλοκων της ορθοπαιδικης ή αγγειακης χειρουργικης και του πολλαπλου τραυματος
KR20250127084A (ko) * 2022-12-02 2025-08-26 시비라이프 조절된 괴사 억제제와 n-아세틸시스테인의 상승작용적 조합

Also Published As

Publication number Publication date
US20170333393A1 (en) 2017-11-23
WO2016086327A1 (es) 2016-06-09

Similar Documents

Publication Publication Date Title
CL2019001433A1 (es) Moduladores de la proteína core de la hepatitis b. (divisional solicitud 201800684)
CL2019003589A1 (es) Derivado de n2,n4-difenilpirimidin-2,4-diamina, método para la preparación del mismo, y una composición farmacéutica que contiene el mismo como ingrediente activo para la prevención o tratamiento de cáncer.
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
ECSP19021223A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
DOP2016000233A (es) MODULADORES ALOSTÉRICOS DE PROTElNA NÚCLEO DE HEPATITIS B
CR20170424A (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsula del vhb
MX2017010304A (es) Composiciones farmaceuticas que comprenden meloxicam.
GT201700167A (es) Terapias de combinación para el tratamiento de cánceres.
NI201600115A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b.
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX2016013245A (es) Regimen de dosificacion de liberacion inmediata de moduladores s1p.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
MX2017008486A (es) Combinaciones del inhibidor de tirosina cinasa de bruton (btk) y regimenes de dosificacion.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
CL2021001636A1 (es) Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
BR112018002530A2 (pt) combinações e usos e tratamentos destas
CO7461127A2 (es) Código para la configuración de un dispositivo de atención al paciente
MX2017015293A (es) Composicion para tratar lesiones tisulares.